Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption

AIDS

Volumn 16, Issue 18, 2002, Pages 2431-2438

  D'Offizi, Gianpiero ^a   Montesano, Carla ^a   Agrati, Chiara ^a   Gioia, Cristiana ^a   Amicosante, Massimo ^a   Topino, Simone ^a   Narciso, Pasquale ^a   Pucillo, Leopoldo Paolo ^a   Ippolito, Giuseppe ^a   Poccia, Fabrizio ^a  

^a Lab Immunopathol P Del Vecchio   (Italy)

Author keywords

CCR7; CD27; CTL; HAART; HIV 1 Gag; Peptides

Indexed keywords

ANTIRETROVIRUS AGENT; CD27 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DIDANOSINE; EFAVIRENZ; GAG PROTEIN; GAMMA INTERFERON; INDINAVIR; LAMIVUDINE; MONOCLONAL ANTIBODY; NELFINAVIR; NEVIRAPINE; PERFORIN; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALE; MEMORY CELL; MONONUCLEAR CELL; NEPHROLITHIASIS; PRIORITY JOURNAL; REBOUND; STRUCTURED TREATMENT INTERRUPTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PILOT PROJECTS; VIRAL LOAD;

EID: 0037032905     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200212060-00008     Document Type: Article

References (24)

1. Markowitz M. Resistance, fitness, adherence, and potency: Mapping the paths to virologic failure. JAMA 2000, 283:250-251.
2. Lori F, Lisziewicz I. Structured treatment interruptions for the management of HIV infection. JAMA 2001, 286:2981-2987.
3. Montaner LJ. Structured treatment interruptions to control HIV-1 and limit drug exposure. Trends Immunol 2001, 22:92-96.
4. McMichael AI, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001, 410:980-987.
5. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
6. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106-111.
7. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000, 12:336-341.
8. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
9. Hintzen RQ, de Jong R, Lens SM, Brouwer M, Baars P, van Lier RA. Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol 1993, 151:2426-2435.
10. Amicosante M, Gioia C, Montesano C, Casetti R, Topino S, D'Offizi G, et al. Computer-based design of an HLA-haplotype and HIV-clade independent CTL assay for monitoring HIV-specific immunity. Mol Med (in press).
11. Betts MR, Casazza JP, Koup RA. Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production. Immunol Lett 2001, 79:117-125.
12. Deleage G, Combet C, Blanchet C, Geourjon C. ANTHEPROT: An integrated protein sequence analysis software with client/server capabilities. Comput Biol Med 2001, 31:259-267.
13. Brander C, Walker BD. T lymphocyte responses in HIV-1 infection: Implications for vaccine development. Curr Opin Immunol 1999, 11:451-459.
14. Rammensee H, Bachmann J, Emmench NP, Bachor OA, Slevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
15. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152:163-175.
16. Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAPrOC: A prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 2001, 53:87-94.
17. Ortiz GM, Wellons M, Brancato I, Vo HT, Zinn RL, Clarkson DE, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001, 98:13288-13293.
18. Mollet L, Li TS, Samri A, Tournay C, Tubiana R, Calvez V, et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol 2000, 165:1692-1704.
19. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997, 186:1407-1418.
20. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001, 14:29-37.
21. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses 1999, 15:1219-1228.
22. Kostense S, Ogg GS, Manting EH, Gillespie G, Joling J, Vandenberghe K, et al. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: Evidence for impaired CTL effector function. Eur J Immunol 2001, 31:677-686.
23. Vogel TU, Allen TM, Altman JD, Watkins DI. Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection. J Virol 2001, 75:2458-2461.
24. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63-75.